# Ferroptosis, Necroptosis, and Pyroptosis in Gastrointestinal Cancers: The Chief Culprits of Tumor Progression and Drug Resistance

**Authors:** Xudong Zhu, Shenglong Li

PMC · DOI: 10.1002/advs.202300824 · Advanced Science · 2023-07-12

## TL;DR

This review explores how ferroptosis, necroptosis, and pyroptosis contribute to gastrointestinal cancer progression and drug resistance, aiming to guide future targeted therapies.

## Contribution

The paper provides a comprehensive summary of the roles and mechanisms of non-apoptotic cell death types in gastrointestinal cancers.

## Key findings

- Ferroptosis, necroptosis, and pyroptosis are linked to tumor progression in gastrointestinal cancers.
- These cell death types induce inflammatory responses and are regulated by specific molecular pathways.
- Understanding these mechanisms may lead to new targeted therapies for gastrointestinal cancers.

## Abstract

In recent years, the incidence of gastrointestinal cancers is increasing, particularly in the younger population. Effective treatment is crucial for improving patients’ survival outcomes. Programmed cell death, regulated by various genes, plays a fundamental role in the growth and development of organisms. It is also critical for maintaining tissue and organ homeostasis and takes part in multiple pathological processes. In addition to apoptosis, there are other types of programmed cell death, such as ferroptosis, necroptosis, and pyroptosis, which can induce severe inflammatory responses. Notably, besides apoptosis, ferroptosis, necroptosis, and pyroptosis also contribute to the occurrence and development of gastrointestinal cancers. This review aims to provide a comprehensive summary on the biological roles and molecular mechanisms of ferroptosis, necroptosis, and pyroptosis, as well as their regulators in gastrointestinal cancers and hope to open up new paths for tumor targeted therapy in the near future.

Programmed cell death mainly include ferroptosis (A), necroptosis (B), and pyroptosis (C), which are morphologically similar and can induce severe inflammatory responses. Notably, ferroptosis, necroptosis, and pyroptosis also participate in the occurrence and development of cancers. Here, the molecular mechanisms of ferroptosis, necroptosis, and pyroptosis are summarized.

## Full-text entities

- **Genes:** LINC00239 (long intergenic non-protein coding RNA 239) [NCBI Gene 145200] {aka C14orf72, NCRNA00239}, PKM (pyruvate kinase M1/2) [NCBI Gene 5315] {aka CTHBP, HEL-S-30, OIP3, PK3, PKM2, TCB}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, FZD3 (frizzled class receptor 3) [NCBI Gene 7976] {aka Fz-3}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, NOX4 (NADPH oxidase 4) [NCBI Gene 50507] {aka KOX, KOX-1, RENOX}, MLKL (mixed lineage kinase domain like pseudokinase) [NCBI Gene 197259] {aka hMLKL}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, TCEA3 (transcription elongation factor A3) [NCBI Gene 6920] {aka TFIIS, TFIIS.H}, SMYD2 (SET and MYND domain containing 2) [NCBI Gene 56950] {aka HSKM-B, KMT3C, ZMYND14}, SIRT3 (sirtuin 3) [NCBI Gene 23410] {aka SIR2L3}, SRSF9 (serine and arginine rich splicing factor 9) [NCBI Gene 8683] {aka SFRS9, SRp30c}, BGN (biglycan) [NCBI Gene 633] {aka DSPG1, MRLS, PG-S1, PGI, SEMDX, SLRR1A}, NEK7 (NIMA related kinase 7) [NCBI Gene 140609], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, FTH1 (ferritin heavy chain 1) [NCBI Gene 2495] {aka FHC, FTH, FTHL6, HFE5, NBIA9, PIG15}, MIR675 (microRNA 675) [NCBI Gene 100033819] {aka MIRN675, hsa-mir-675}, CFLAR (CASP8 and FADD like apoptosis regulator) [NCBI Gene 8837] {aka CASH, CASP8AP1, CLARP, Casper, FLAME, FLAME-1}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, FADD (Fas associated via death domain) [NCBI Gene 8772] {aka GIG3, IMD90, MORT1}, HSPB2 (heat shock protein family B (small) member 2) [NCBI Gene 3316] {aka HSP27, Hs.78846, LOH11CR1K, MKBP}, MIR372 (microRNA 372) [NCBI Gene 442917] {aka MIRN372, hsa-mir-372}, H19 (H19 imprinted maternally expressed transcript) [NCBI Gene 283120] {aka ASM, ASM1, BWS, D11S813E, GMRSP, LINC00008}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, GABPB1 (GA binding protein transcription factor subunit beta 1) [NCBI Gene 2553] {aka BABPB2, E4TF1, E4TF1-47, E4TF1-53, E4TF1B, GABPB}, CASP8 (caspase 8) [NCBI Gene 841] {aka ALPS2B, CAP4, Casp-8, FLICE, MACH, MCH5}, PGP (phosphoglycolate phosphatase) [NCBI Gene 283871] {aka AUM, G3PP, PGPase}, NUP62 (nucleoporin 62) [NCBI Gene 23636] {aka IBSN, SNDI, p62}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, BCL2L1 (BCL2 like 1) [NCBI Gene 598] {aka BCL-XL/S, BCL2L, BCLX, Bcl-X, PPP1R52}, APOC1 (apolipoprotein C1) [NCBI Gene 341] {aka APOC1B, Apo-CI, ApoC-I, apo-CIB, apoC-IB}, POR (cytochrome p450 oxidoreductase) [NCBI Gene 5447] {aka CPR, CYPOR, P450R}, ZEB1 (zinc finger E-box binding homeobox 1) [NCBI Gene 6935] {aka AREB6, BZP, DELTAEF1, FECD6, NIL2A, PPCD3}, ATF3 (activating transcription factor 3) [NCBI Gene 467], SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, FBXW7 (F-box and WD repeat domain containing 7) [NCBI Gene 55294] {aka AGO, CDC4, DEDHIL, FBW6, FBW7, FBX30}, SORD (sorbitol dehydrogenase) [NCBI Gene 6652] {aka HEL-S-95n, HMNR8, RDH, SDH, SORD1, SORDD}, MIR448 (microRNA 448) [NCBI Gene 554212] {aka MIRN448, hsa-mir-448, miRNA448}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, GJB1 (gap junction protein beta 1) [NCBI Gene 2705] {aka CMTX, CMTX1, CX32}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, CDK2 (cyclin dependent kinase 2) [NCBI Gene 1017] {aka CDKN2, p33(CDK2)}, CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026] {aka CAP20, CDKN1, CIP1, MDA-6, P21, SDI1}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, HNRNPA1 (heterogeneous nuclear ribonucleoprotein A1) [NCBI Gene 3178] {aka ALS19, ALS20, HNRPA1, HNRPA1L3, IBMPFD3, MPD3}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, SNHG7 (small nucleolar RNA host gene 7) [NCBI Gene 84973] {aka NCRNA00061}, IL18 (interleukin 18) [NCBI Gene 3606] {aka IGIF, IL-18, IL-1g, IL1F4}, G6PD (glucose-6-phosphate dehydrogenase) [NCBI Gene 2539] {aka CNSHA1, G6PD1}, Slc7a11 (solute carrier family 7 (cationic amino acid transporter, y+ system), member 11) [NCBI Gene 26570] {aka 9930009M05Rik, sut, xCT}, SCD (stearoyl-CoA desaturase) [NCBI Gene 6319] {aka FADS5, MSTP008, SCD1, SCDOS, hSCD1}, PCSK1 (proprotein convertase subtilisin/kexin type 1) [NCBI Gene 5122] {aka BMIQ12, NEC1, PC1, PC1/3, PC3, SPC3}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, SLC7A1 (solute carrier family 7 member 1) [NCBI Gene 6541] {aka ATRC1, CAT-1, ERR, HCAT1, REC1L}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, TMBIM4 (transmembrane BAX inhibitor motif containing 4) [NCBI Gene 51643] {aka CGI-119, GAAP, LFG4, S1R, ZPRO}, TFRC (transferrin receptor) [NCBI Gene 7037] {aka CD71, IMD46, T9, TFR, TFR1, TR}, KRAS (KRAS proto-oncogene, GTPase) [NCBI Gene 3845] {aka 'C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A}
- **Diseases:** Hypoxic (MESH:D002534), cytotoxic (MESH:D064420), HCC (MESH:D006528), PCD (MESH:D003643), peritoneal metastases (MESH:D010538), lymph node metastasis (MESH:D008207), IIb (MESH:D006938), GI cancers (MESH:D005770), necrosis (MESH:D009336), mitochondrial damage (MESH:D028361), rectal cancer (MESH:D012004), ESCC (MESH:D000077277), dysplasia (MESH:D015792), adenomatous polyps (MESH:D018256), iron deficiency anemia (MESH:D018798), Cancers (MESH:D009369), esophageal cancer (MESH:D004938), hypoxia (MESH:D000860), adenocarcinoma (MESH:D000230), inflammatory bowel diseases (MESH:D015212), metastasis (MESH:D009362), Infection (MESH:D007239), carcinogenesis (MESH:D063646), colorectal adenoma (MESH:D000236), GSDME (MESH:D016751), prolapse (MESH:D011391), CRC (MESH:D015179), RCC (MESH:D002292), aggression (MESH:D010554), ulcerative colitis (MESH:D003093), mesenchymal (MESH:C535700), GC (MESH:D013274), chronic inflammation (MESH:D007249)
- **Chemicals:** Cu (MESH:D003300), 5-FU (MESH:D005472), Lenvatinib (MESH:C531958), potassium (MESH:D011188), Fenofibrate (MESH:D011345), Fe (MESH:D007501), erastin (MESH:C477224), glucose (MESH:D005947), Ergothioneine (MESH:D004880), n-3 polyunsaturated fatty acid (MESH:D015525), glutamate (MESH:D018698), SiO2 (MESH:D012822), cysteine (MESH:D003545), GSSG (MESH:D019803), Dimethyl fumarate (MESH:D000069462), manganese (MESH:D008345), L-OHP (MESH:D000077150), paclitaxel (MESH:D017239), YVAD-cmk (MESH:C098738), cisplatin (MESH:D002945), doxorubicin (MESH:D004317), GA (MESH:C052659), phospholipids (MESH:D010743), BIX-01294 (MESH:C518299), Astaxanthin (MESH:C005948), beta-elemene (MESH:C445979), monounsaturated fatty acids (MESH:D005229), 17beta-estradiol (MESH:D004958), GV (MESH:D005840), H2O2 (MESH:D006861), aspirin (MESH:D001241), N-acetylcysteine (MESH:D000111), necrostatin-1 (MESH:C507699), Au(C^C-2-NC5H4) (-), MDA (MESH:D015104), rhamnetin (MESH:C063423), hydroxyl radicals (MESH:D017665), curcumin (MESH:D003474), Chlorin e6 (MESH:C062985), SDG (MESH:C060283), PUFAs (MESH:D005231), ATO (MESH:D000077237), MF-438 (MESH:C548713), tagitinin C (MESH:C012565), Cetuximab (MESH:D000068818), alpha-ketoglutarate (MESH:D007656), Metformin (MESH:D008687), Cu (I) (MESH:C073870), cholesterol (MESH:D002784), FL118 (MESH:C578515), Camptothecin (MESH:D002166), Resibufogenin (MESH:C005734), rhamnolipids (MESH:C418382), apatinib (MESH:C553458), LPS (MESH:D008070), Alpinumisoflavone (MESH:C000154), HUHS1015 (MESH:C586405), Elesclomol (MESH:C512195), SO2 (MESH:D013458), GSH (MESH:D005978)
- **Species:** Helicobacter pylori (species) [taxon 210], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Homo sapiens (human, species) [taxon 9606], Hepatitis B virus (no rank) [taxon 10407], Orthopoxvirus vaccinia (species) [taxon 10245]
- **Mutations:** P13K, serine residue 358
- **Cell lines:** LU-BAC — Mus musculus (Mouse), Transformed cell line (CVCL_6770), MKN45 — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0434), AGS — Homo sapiens (Human), Gastric adenocarcinoma, Cancer cell line (CVCL_0139), HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), Hep3B — Homo sapiens (Human), Childhood hepatocellular carcinoma, Cancer cell line (CVCL_0326), HGC-27 — Homo sapiens (Human), Gastric carcinoma, Cancer cell line (CVCL_1279), HepG2/DDP — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_C869), MKN28 — Homo sapiens (Human), Gastric tubular adenocarcinoma, Cancer cell line (CVCL_1416)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10502844/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC10502844/full.md

## References

215 references — full list in the complete paper: https://tomesphere.com/paper/PMC10502844/full.md

---
Source: https://tomesphere.com/paper/PMC10502844